FIELD: medicine.
SUBSTANCE: invention relates to a new compound (1) characterized by an effect of remodeling tumor vessels and/or activity against cancer-associated fibroblasts (CAF) or its pharmaceutically acceptable salt, as well as to a pharmaceutical composition based on it, and the use for the treatment of tumor or cancer.
EFFECT: new compound is obtained, which can be used for the treatment of tumor or cancer, wherein cancer or tumor is head and neck cancer, breast cancer, esophageal cancer, uterine cancer, ovarian cancer, colon and rectal cancer, endometrial cancer, stomach cancer, small bowel cancer, bladder cancer, or sarcoma.
78 cl, 27 ex, 17 tbl, 18 dwg
Title | Year | Author | Number |
---|---|---|---|
DIARYLTHIOHYDATOIC COMPOUNDS | 2007 |
|
RU2449993C2 |
MONOCYCLIC PYRIDINE DERIVATIVE | 2014 |
|
RU2645352C2 |
SUBSTITUTED QUINOLINE COMPOUNDS AND METHODS OF THEIR APPLICATION | 2012 |
|
RU2568258C2 |
MEK INHIBITORS AND THEIR THERAPEUTIC USE | 2021 |
|
RU2812929C1 |
INHIBITORS OF NOTCH SIGNAL TRANSMISSION WAYS AND THEIR APPLICATION FOR CANCER TREATMENT | 2012 |
|
RU2631611C2 |
2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE OF SAID COMPOUND | 2015 |
|
RU2704129C2 |
FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOF | 2015 |
|
RU2676766C2 |
CYCLIC DI-NUCLEOTIDE COMPOUNDS FOR TREATMENT OF CANCER | 2018 |
|
RU2790175C2 |
ANILINE PYRIMIDINE DERIVATIVES AND USE THEREOF | 2016 |
|
RU2734849C2 |
NOVEL S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | 2011 |
|
RU2585763C2 |
Authors
Dates
2022-11-10—Published
2018-04-03—Filed